DE69434294D1 - Proteinkinase c-inhibitoren - Google Patents

Proteinkinase c-inhibitoren

Info

Publication number
DE69434294D1
DE69434294D1 DE69434294T DE69434294T DE69434294D1 DE 69434294 D1 DE69434294 D1 DE 69434294D1 DE 69434294 T DE69434294 T DE 69434294T DE 69434294 T DE69434294 T DE 69434294T DE 69434294 D1 DE69434294 D1 DE 69434294D1
Authority
DE
Germany
Prior art keywords
beta
protein kinase
inhibitors
isozyme
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69434294T
Other languages
English (en)
Other versions
DE69434294T2 (de
Inventor
Francis Heath
Hampton Mcdonald
Michael Paal
Gerd Ruether
Theo Schotten
Wolfgang Stenzel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/324,948 external-priority patent/US5545636A/en
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Application granted granted Critical
Publication of DE69434294D1 publication Critical patent/DE69434294D1/de
Publication of DE69434294T2 publication Critical patent/DE69434294T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69434294T 1993-12-23 1994-12-14 Proteinkinase c-inhibitoren Expired - Lifetime DE69434294T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US17374193A 1993-12-23 1993-12-23
US173741 1993-12-23
US08/324,948 US5545636A (en) 1993-12-23 1994-10-18 Protein kinase C inhibitors
US324948 1994-10-18
PCT/US1994/014313 WO1995017182A1 (en) 1993-12-23 1994-12-14 Protein kinase c inhibitors

Publications (2)

Publication Number Publication Date
DE69434294D1 true DE69434294D1 (de) 2005-04-14
DE69434294T2 DE69434294T2 (de) 2005-12-29

Family

ID=26869484

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69434294T Expired - Lifetime DE69434294T2 (de) 1993-12-23 1994-12-14 Proteinkinase c-inhibitoren

Country Status (13)

Country Link
US (3) US5668152A (de)
EP (2) EP0817627B1 (de)
JP (4) JP3998261B2 (de)
AT (2) ATE456367T1 (de)
AU (1) AU1339895A (de)
CA (1) CA2179650C (de)
DE (1) DE69434294T2 (de)
DK (1) DK0817627T3 (de)
ES (1) ES2236702T3 (de)
HK (1) HK1008183A1 (de)
PT (1) PT817627E (de)
SI (1) SI0817627T1 (de)
WO (1) WO1995017182A1 (de)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20000064764A (ko) * 1996-03-20 2000-11-06 피터지.스트링거 인돌릴말레이미드의제조방법
US6232299B1 (en) * 1996-05-01 2001-05-15 Eli Lilly And Company Use of protein kinase C inhibitors to enhance the clinical efficacy of oncolytic agents and radiation therapy
SE9603285D0 (sv) * 1996-09-10 1996-09-10 Astra Ab New compounds
SE9603284D0 (sv) * 1996-09-10 1996-09-10 Astra Ab New compounds
SE9603283D0 (sv) * 1996-09-10 1996-09-10 Astra Ab New compounds
TW472045B (en) 1996-09-25 2002-01-11 Astra Ab Protein kinase C inhibitor compounds, method for their preparation, pharmaceutical composition thereof and intermediate used for their preparation
US5859261A (en) * 1997-03-20 1999-01-12 Eli Lilly And Company Synthesis of indolylmaleimides
AR017200A1 (es) 1997-12-23 2001-08-22 Astrazeneca Ab Compuestos inhibidores de la proteina cinasa c, sales farmaceuticamente aceptables de los mismos, formulaciones farmaceuitcas que los comprenden, usode las mismas y proceso para la sintesis de dichos compuestos
SE9800835D0 (sv) 1998-03-13 1998-03-13 Astra Ab New Compounds
TR200002580T2 (tr) * 1998-03-17 2000-11-21 F.Hoffmann-La Roche Ag Hücre çoğalmasının engellenmesinde kullanılan ikameli bisindolimaleimitler
EP1109785B1 (de) 1998-05-04 2003-01-02 Zentaris AG Indolderivate und deren verwendung zur behandlung von malignen und anderen, auf pathologischen zellproliferationen beruhenden erkrankungen
US6127401A (en) * 1998-06-05 2000-10-03 Cephalon, Inc. Bridged indenopyrrolocarbazoles
US6013646A (en) * 1998-07-02 2000-01-11 Bayer Corporation Indolocarbazole derivatives useful for the treatment of neurodegenerative diseases and cancer
US6841567B1 (en) 1999-02-12 2005-01-11 Cephalon, Inc. Cyclic substituted fused pyrrolocarbazoles and isoindolones
US6492406B1 (en) 1999-05-21 2002-12-10 Astrazeneca Ab Pharmaceutically active compounds
US6284783B1 (en) 1999-06-09 2001-09-04 The Uab Research Foundation Use of bisindolylmaleimide compounds to induce Fas-mediated apoptosis
US6346625B1 (en) 1999-06-23 2002-02-12 Astrazeneca Ab Protein kinase inhibitors
CN1158258C (zh) 1999-06-24 2004-07-21 东丽株式会社 肾上腺素能α1B受体拮抗药
US6399780B1 (en) 1999-08-20 2002-06-04 Cephalon, Inc. Isomeric fused pyrrolocarbazoles and isoindolones
EP1242420A2 (de) * 1999-12-16 2002-09-25 Eli Lilly And Company Mittel und verfahren zur behandlung von proliferativen erkrankungen
US6743785B2 (en) 1999-12-16 2004-06-01 Eli Lilly And Company Agents and methods for the treatment of proliferative diseases
DE60010934T2 (de) * 1999-12-16 2005-05-19 Eli Lilly And Co., Indianapolis Medikamente geeignet zur Behandlung von proliferativen Erkrankungen
ATE366238T1 (de) * 2000-05-11 2007-07-15 Consejo Superior Investigacion Heterocyclischen inhibitoren von glycogen synthase kinase gsk-3
ES2166328B1 (es) * 2000-05-11 2003-09-16 Consejo Superior Investigacion Inhibidores heterociclicos del enzima gsk 3 utiles en el tratamiento de procesos neurodegenerativos e hiperproliferativos
AU2001271257A1 (en) * 2000-06-29 2002-01-14 Eli Lilly And Company Use of a protein kinase c inhibitor to enhance the clinical efficacy of anti-neoplastic chemotherapeutic agents and radiation therapy
AU2001271261A1 (en) * 2000-06-29 2002-01-14 Eli Lilly And Company Therapeutic treatment of cancer with a protein kinase c inhibitor
PT1362047E (pt) 2000-12-08 2006-09-29 Ortho Mcneil Pharm Inc Compostos de pirrolina substituidos com indazolilo como inibidores de cinase
WO2003103663A2 (en) 2002-06-05 2003-12-18 Janssen Pharmaceutica N.V. Substituted pyrrolines as kinase inhibitors
KR20050008787A (ko) * 2002-06-05 2005-01-21 얀센 파마슈티카 엔.브이. 키나제 저해제로서의 비스인돌릴-말레이미드 유도체
CA2393720C (en) * 2002-07-12 2010-09-14 Eli Lilly And Company Crystalline 2,5-dione-3-(1-methyl-1h-indol-3-yl)-4-[1-(pyridin-2-ylmethyl)piperidin-4-yl]-1h-indol-3-yl]-1h-pyrrole mono-hydrochloride
DE10244453A1 (de) 2002-09-24 2004-04-01 Phenomiques Gmbh Hemmung der Proteinkinase C-alpha zur Behandlung von Krankheiten
ATE400268T1 (de) * 2003-10-24 2008-07-15 Lilly Co Eli Bisindolylmaleimid zur behandlung von prostatakrebs und akt-vermittelten erkrankungen
GB0513881D0 (en) 2005-07-06 2005-08-10 Btg Int Ltd Core 2 GLCNAC-T Inhibitors III
GB0329667D0 (en) 2003-12-22 2004-01-28 King S College London Core 2 GlcNAc-T inhibitor
US20080182801A1 (en) 2003-12-22 2008-07-31 Btg International Limited Core 2 glcnac-t inhibitors
WO2006002422A2 (en) 2004-06-24 2006-01-05 Novartis Vaccines And Diagnostics Inc. Compounds for immunopotentiation
EP2289892B1 (de) 2005-02-09 2012-08-22 ArQule, Inc. Maleimid-derivate, pharmazeutischen Zusammensetzungen, und Verfahren zur Krebsbehandlung
WO2006108270A1 (en) * 2005-04-11 2006-10-19 Pharmagap Inc. Inhibitors of protein kinases and uses thereof
GB0513888D0 (en) 2005-07-06 2005-08-10 Btg Int Ltd Core 2 GLCNAC-T Inhibitors II
KR20080023732A (ko) * 2005-07-11 2008-03-14 노파르티스 아게 인돌릴말레이미드 유도체
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
GB0605691D0 (en) * 2006-03-21 2006-05-03 Novartis Ag Organic Compounds
AR060358A1 (es) 2006-04-06 2008-06-11 Novartis Vaccines & Diagnostic Quinazolinas para la inhibicion de pdk 1
US8513292B2 (en) 2007-06-22 2013-08-20 Arqule, Inc. Compositions and methods for the treatment of cancer
AU2008268613A1 (en) 2007-06-22 2008-12-31 Arqule, Inc. Quinazolinone compounds and methods of use thereof
JP5425060B2 (ja) 2007-06-22 2014-02-26 アークル インコーポレイテッド ピロリジノン、ピロリジン−２，５−ジオン、ピロリジンおよびチオスクシンイミド誘導体、癌の治療のための組成物および方法
PE20091523A1 (es) 2007-12-20 2009-10-29 Novartis Ag Derivados de tiazol como inhibidores de la enzima fosfatidilinositol 3-cinasa (pi3k)
WO2010019225A1 (en) * 2008-08-15 2010-02-18 Robert Shorr Pharmaceutical composition
CN102245184A (zh) 2008-12-15 2011-11-16 伊莱利利公司 用于治疗癌症的恩扎妥林
US8293753B2 (en) 2009-07-02 2012-10-23 Novartis Ag Substituted 2-carboxamide cycloamino ureas
EP2552428A1 (de) 2010-03-30 2013-02-06 Novartis AG Pkc-hemmer zur behandlung von b-zell-lymphom mit chronischer aktiver b-zell-rezeptorsignalisierung
AR082418A1 (es) 2010-08-02 2012-12-05 Novartis Ag Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico
PT2670753T (pt) 2011-01-31 2017-01-10 Novartis Ag Novos derivados heterocíclicos
EP2567959B1 (de) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridin-4-carbonsäureamid-derivate als kinaseinhibitoren
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US8846712B2 (en) 2011-09-12 2014-09-30 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (de) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridin-4-carbonsäureamidderivate als kinaseinhibitoren
CN104039790B (zh) 2011-10-28 2016-04-13 诺华股份有限公司 嘌呤衍生物及它们在治疗疾病中的应用
HUE029402T2 (en) 2012-03-16 2017-02-28 Vitae Pharmaceuticals Inc Liver X receptor modulators
HUE030785T2 (en) 2012-03-16 2017-06-28 Vitae Pharmaceuticals Inc Liver X receptor modulators
WO2013167403A1 (en) 2012-05-09 2013-11-14 Sanofi Substituted 6-(4-hydroxy-phenyl)-1h-pyrazolo[3,4-b]pyridine derivatives as kinase inhibitors
EP2849756A1 (de) 2012-05-16 2015-03-25 Novartis AG Dosierungsplan für einen pi-3-kinaseinhibitor
EP2925366B1 (de) 2012-11-29 2018-02-21 Novartis AG Pharmazeutische kombinationen
WO2014174478A1 (en) 2013-04-26 2014-10-30 Novartis Ag Pharmaceutical combinations of a pkc inhibitor and a c-met receptor tyrosine kinase inhibitor
EP3076969B1 (de) 2013-12-06 2021-09-01 Novartis AG Dosierungsschema für einen alpha-isoform-selektiven phosphatidylinositol-3-kinase-hemmer
US20170216286A1 (en) 2014-01-28 2017-08-03 Mayo Foundation For Medical Education And Research Killing senescent cells and treating senescence-associated conditions using a src inhibitor and a flavonoid
JO3589B1 (ar) 2014-08-06 2020-07-05 Novartis Ag مثبطات كيناز البروتين c وطرق استخداماتها
CN104398508B (zh) * 2014-11-28 2017-06-13 上海交通大学 双吲哚马来酰亚胺衍生物在制备治疗慢性粒细胞白血病药物中的应用
KR20180073674A (ko) 2015-11-02 2018-07-02 노파르티스 아게 포스파티딜이노시톨 3-키나제 억제제에 대한 투여 요법
US10112924B2 (en) 2015-12-02 2018-10-30 Astraea Therapeutics, Inc. Piperdinyl nociceptin receptor compounds
EP4455145A2 (de) * 2015-12-02 2024-10-30 Astraea Therapeutics, LLC Piperidinyl-nociceptin-rezeptorverbindungen
CN106083830B (zh) * 2016-06-01 2019-07-12 中国海洋大学 双吲哚马来酰亚胺衍生物及其制备方法和用途
CN106146475B (zh) * 2016-06-01 2019-05-17 中国海洋大学 双吲哚马来酰亚胺衍生物及其制备方法和用途
JOP20190025A1 (ar) 2016-09-01 2019-02-19 Denovo Biopharma Llc طرق وتركيبة لتوقع نشاط إنزاستورين
WO2018060833A1 (en) 2016-09-27 2018-04-05 Novartis Ag Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib
WO2019000224A1 (zh) * 2017-06-27 2019-01-03 中国海洋大学 双吲哚马来酰亚胺衍生物及其制备方法和用途

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4785085A (en) * 1986-11-21 1988-11-15 Bristol-Myers Company Rebeccamycin analogs
US4808613A (en) * 1986-11-21 1989-02-28 Bristol-Myers Company Rebeccamycin derivative containing pharmaceutical composition
US4923986A (en) * 1987-03-09 1990-05-08 Kyowa Hakko Kogyo Co., Ltd. Derivatives of physiologically active substance K-252
DE3803620A1 (de) * 1988-02-06 1989-08-17 Goedecke Ag Indolocarbazol-derivate, verfahren zu deren herstellung und diese enthaltende arzneimittel
SK278989B6 (sk) * 1988-02-10 1998-05-06 F. Hoffmann-La Roche Ag Substituované pyroly, ich použitie na výrobu lieči
MC2096A1 (fr) 1989-02-23 1991-02-15 Hoffmann La Roche Pyrroles substitues
CA2015996C (en) 1989-05-05 2001-08-28 Hartmut Osswald Bis-(1h-indol-3-yl)-maleinimide derivatives and their use as pharmaceuticals
US5380746A (en) * 1989-05-05 1995-01-10 Goedecke Aktiengesellschaft Bis-(1H-indol-3-YL)-maleinimide derivatives, processes for the preparation thereof and pharmaceutical compositions containing them
DE3942991A1 (de) * 1989-12-27 1991-07-04 Goedecke Ag Maleinimid-derivate und deren verwendung als arzneimittel
DE3914764A1 (de) * 1989-05-05 1990-11-08 Goedecke Ag Maleinimid-derivate und deren verwendung als arzneimittel
DE3942296A1 (de) * 1989-12-21 1991-06-27 Goedecke Ag Indolocarbazol-derivate, verfahren zu deren herstellung und deren verwendung
DE4005970A1 (de) * 1990-02-26 1991-08-29 Boehringer Mannheim Gmbh Neue trisubstituierte maleinimide, verfahren zu ihrer herstellung sowie arzneimittel, die diese verbindungen enthalten
DE4005969A1 (de) * 1990-02-26 1991-08-29 Boehringer Mannheim Gmbh Neue trisubstituierte pyrrole, verfahren zu ihrer herstellung sowie arzneimittel, die diese verbindungen enthalten
CA2046801C (en) * 1990-08-07 2002-02-26 Peter D. Davis Substituted pyrroles
US5292747A (en) * 1990-08-07 1994-03-08 Hoffman-La Roche Inc. Substituted pyrroles
EP0580609A1 (de) * 1991-03-22 1994-02-02 Xenova Limited Pharmazeutische xanthonderivate
GB9123396D0 (en) * 1991-11-04 1991-12-18 Hoffmann La Roche A process for the manufacture of substituted maleimides
AU3761393A (en) * 1992-03-20 1993-10-21 Wellcome Foundation Limited, The Indole derivatives with antiviral activity
US5461146A (en) * 1992-07-24 1995-10-24 Cephalon, Inc. Selected protein kinase inhibitors for the treatment of neurological disorders
DE4243321A1 (de) * 1992-12-21 1994-06-23 Goedecke Ag Aminosäurederivate von Heterocyclen als PKC-Inhibitoren
AU678435B2 (en) * 1993-05-10 1997-05-29 F. Hoffmann-La Roche Ag Substituted pyrroles
US5481003A (en) * 1994-06-22 1996-01-02 Eli Lilly And Company Protein kinase C inhibitors

Also Published As

Publication number Publication date
US5661173A (en) 1997-08-26
WO1995017182A1 (en) 1995-06-29
ATE456367T1 (de) 2010-02-15
ES2236702T3 (es) 2005-07-16
EP1449529A1 (de) 2004-08-25
JPH09507066A (ja) 1997-07-15
EP0817627A1 (de) 1998-01-14
DE69434294T2 (de) 2005-12-29
US5672618A (en) 1997-09-30
JP4490400B2 (ja) 2010-06-23
PT817627E (pt) 2005-07-29
SI0817627T1 (de) 2005-08-31
EP0817627A4 (de) 2002-07-17
JP4365803B2 (ja) 2009-11-18
CA2179650A1 (en) 1995-06-29
AU1339895A (en) 1995-07-10
DK0817627T3 (da) 2005-06-06
ATE290378T1 (de) 2005-03-15
JP3998261B2 (ja) 2007-10-24
EP1449529B1 (de) 2010-01-27
JP2005225895A (ja) 2005-08-25
JP4369397B2 (ja) 2009-11-18
HK1008183A1 (en) 1999-05-07
EP0817627B1 (de) 2005-03-09
US5668152A (en) 1997-09-16
JP2005225896A (ja) 2005-08-25
JP2006316068A (ja) 2006-11-24
CA2179650C (en) 2007-10-30

Similar Documents

Publication Publication Date Title
ATE456367T1 (de) Proteinkinase c inhibitoren
DK0766682T3 (da) Proteinkinase-C-inhibitorer
CA2376596A1 (en) Humanized anti-erbb2 antibodies and treatment with anti-erbb2 antibodies
EP1040827A3 (de) Verwendung von 3,4-dihydroxy-2-hydroxymethylpyrrolidin zur behandlung von diabetes
BG103671A (en) Combinations of sulphonylcarbamide-glytazone having synergetic effect for the treatment of diabetes
NO900853D0 (no) Slitebane for kjoeretoeydekk med midtre partier forsynt medskraa innsnitt.
AU2002366641A1 (en) Methods for inhibiting ocular processes
NZ324921A (en) Cathepsin K crystal structure and methods of identifying inhibitors of this protease
WO2005044093A3 (en) Delta-9- the treatment of multiple sclerosis
DK1027207T3 (da) Fremgangsmåde til at behandle en artikel indeholdende en oxiderbar organisk forbindelse
GB2297691B (en) Method for improving breeding activity of boars by using feed for the breeding boars
WO1995006764A3 (en) Oligonucleotides with rna cleavage activity
IT1240486B (it) Procedimento di ammollo enzimatico per pelli e pellami.
WO1993015112A3 (en) COMPOUNDS AND METHODS FOR INHIBITING β-PROTEIN FUNCTION
DE3861462D1 (de) Gasfeuerzeugstruktur, geeignet zur andrueckmontage seiner hauptteile.
IL142220A0 (en) Method of treating viral hemorrhagic fever
WO2001087239A3 (en) Methods of affecting laminin 5 processing
ITGE930084A0 (it) Sicura,in particolare per fucili subaquei o simili.
WO2000000634A3 (en) METHODS OF INHIBITING $i(HELICOBACTER PYLORI)
BR9915572A (pt) Processo de tratamento de doença de célula falciforme e talassemia
BR9915317A (pt) Método de tratar trombocitopenia induzida por heparina
WO2000058506A3 (en) Susceptibility to psoriasis
EP0646651A3 (de) Verfahren zur Verbesserung der Lederbehandlung.
CA2193703A1 (en) Protein kinase c inhibitors
EP0950411B8 (de) Verfahren zur Herstellung eines Extraktes aus Copalchirinde und Verwendung der Neoflavonoide zur Behandlung von Diabetes

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: KROHER, STROBEL RECHTS- UND PATENTANWAELTE, 80336

8328 Change in the person/name/address of the agent

Representative=s name: DR. SCHOEN & PARTNER, 80336 MUENCHEN